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Abstract 
Major depressive disorder (MDD) is the most common mood disorder in the United 
States and European Union; however, the limitations of clinically available antidepressant drugs 
have led researchers to pursue novel pharmacological treatments. Clinical studies have reported 
that monotherapy with the atypical antipsychotic drug quetiapine produces a rapid reduction in 
depressive symptoms that are apparent following one week of quetiapine treatment, and it is 
possible that the active metabolite N-Desalkylquetiapine, which structurally resembles an 
antidepressant drug, produces antidepressant effects. Neuropharmacological evaluations of the 
neurotensin NTS1 receptor agonist PD149163 are suggestive of antidepressant efficacy, but the 
effects of a NTS1 receptor agonist in an antidepressant animal model have yet to be reported. The 
present study examined the antidepressant-like effects of the N-Desalkylquetiapine, the 
neurotensin NTS1 receptor agonist PD14916, quetiapine, the tricylic antidepressant drug 
imipramine, the atypical antipsychotic drug risperidone, and the typical antipsychotic drug 
raclopride on responding in male Sprague-Dawley rats trained on a differential-reinforcement-of-
low-rate (DRL) 72 s operant schedule, a procedure used for screening antidepressant drugs. 
Quetiapine, PD149163, risperidone, and imipramine exhibited antidepressant-like effects by 
increasing the number of reinforcers earned, decreasing the number of responses emitted, and 
shifting the interresponse time (IRT) distributions to the right. N-Desalkylquetiapine produced a 
partial antidepressant-like effect by decreasing the number of responses emitted and producing a 
rightward shift in the IRT distributions, but it did not significantly alter the number of reinforcers 
earned. The typical antipsychotic drug raclopride decreased both reinforcers and responses. 
These data suggest that N-Desalklyquetiapine likely contributes to quetiapine’s antidepressant 
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efficacy and identifies NTS1 receptor activation as a potential novel pharmacologic strategy for 
antidepressant drugs. 
Keywords: N-Desalklyquetiapine; PD149613; Quetiapine; differential-reinforcement-of-
low-rate (DRL); neurotensin; depression 
 
  
ANTIDEPRESSANT EFFECTS OF N-DESALKYLQUETIAPINE AND PD149163 5 
Disclosures and Acknowledgments 
The study was funded, in part, by a National Institute of Health grant award to Adam J. 
Prus (1R15MH083241). PD149163 was provided by the NIMH Drug Repository and N-
Desalkylquetiapine was a gift from NeuroDetective International. 
All authors contributed in a significant way to the manuscript and all authors have read 
and approved the final manuscript. 
The authors have no conflicts of interest to declare. 
  
ANTIDEPRESSANT EFFECTS OF N-DESALKYLQUETIAPINE AND PD149163 6 
The quetiapine active metabolite N-Desalkylquetiapine and the neurotensin NTS1 receptor 
agonist PD149163 exhibit antidepressant-like effects on operant responding in male rats 
 
Major depressive disorder (MDD) is a recurring and debilitating mental disorder with a 
lifetime prevalence of 14.4% in the United States (Kessler, Petukhova, Sampson, Zaslavsky & 
Wittchen, 2012). Clinicians have several types pharmacological treatments available for MDD, 
which include newer (i.e. selective-serotonin reuptake inhibitors [SSRI] and serotonin-
norepinephrine reuptake inhibitors [SNRI]), older (i.e. tricyclic antidepressants [TCA] and 
monoamine oxidase inhibitors [MAOI]), and atypical (e.g., bupropion and vortioxetine) 
antidepressant medications. However, only about one-half of patients achieve a significant 
attenuation of symptoms, although not complete symptom remission.  Moreover, the delayed 
onset for an attenuation of symptoms remains a concern for clinically available antidepressant 
drugs (Fava & Davidson, 1996; Rush et al., 2006; Schulberg, Katon, Simon, & Rush, 1998). 
Novel strategies for antidepressant drugs include glutamatergic antagonists, such as ketamine 
(Murrough et al., 2013; Zarate et al., 2006), monotherapy with certain atypical antipsychotic 
drugs, such as quetiapine (Bortnick et al., 2011; Cutler et al., 2009), and endogenous substances 
that may broadly alter monoaminergic neurotransmission, such as the neuropeptide neurotensin. 
The atypical antipsychotic drug quetiapine XR (quetiapine fumarate extended release 
tablets) has been approved by the United States Food and Drug Administration (FDA) as an 
adjunctive treatment to antidepressants for MDD patients with inadequate response to 
antidepressant treatment alone. Additionally, quetiapine has shown promise as monotherapy for 
the treatment of MDD in both clinical and preclinical studies. For example, several clinical 
studies have shown that once-daily quetiapine XR (50-300 mg/d) produces a rapid reduction in 
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depressive symptoms after one week of treatment and continues to reduce depressive symptoms 
for six to eight weeks (i.e. the completion of the study) (Bortnick et al., 2011; Cutler et al., 2009; 
Weisler et al., 2009). In animals, quetiapine produces antidepressant-like effects in the forced 
swim test and in behavioral tests following a period of chronic mild stress (Kotagale, Mendhi, 
Aglawe, Umekar, & Taksande, 2013; Orsetti et al., 2007; Orsetti, Brisco, Rinaldi, Dallorto, & 
Ghi, 2009). 
Quetiapine has a diverse pharmacological binding profile with high affinities for 
histamine (H1) receptors and adrenergic (α1A, α1B, α2C) adrenoceptors, and moderate affinities for 
serotonin (5-HT1A, 5-HT2A, 5-HT7) and dopamine (D2) receptors (Jensen et al., 2008; Kroeze et 
al., 2003; Lopez-Munoz & Alamo, 2013). The active metabolite of quetiapine, N-
desalkylquetiapine, which structurally resembles the tetracyclic antidepressant drugs amoxapine 
and the TCA desipramine, likely contributes to the antidepressant effects of quetiapine and has 
high affinities for norepinephrine transporters (NET) and serotonergic (5-HT1A, 5-HT2A, 5-HT2B, 
5-HT7), histaminergic (H1), and muscarinic (M1, M3, M5) receptors (Jensen et al., 2008). 
Moreover, N-desalkylquetiapine has reduced immobility in a tail-suspension test without 
increasing locomotor activity in an open field in mice, and these effects are representative of 
clinically-effective antidepressant drugs in animal models (Jensen et al., 2008).  
Neurotensin is a widely distributed neuropeptide neurotransmitter that is synthesized and 
released from dopamine and other neurons and has extensive interactions, primarily via NTS1 
receptors, with monoamine, cholinergic, GABAergic, and glutamatergic neurons (Binder, 
Kinkead, Owens, & Nemeroff, 2001; St-Gelais, Jomphe, & Trudeau, 2006). These interactions 
have led to investigations into the potential role of neurotensin in the pathophysiology of central 
nervous system disorders (St-Gelais et al., 2006) and the evaluation of brain-penetrant 
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neurotensin receptor agonists for the treatment pain (e.g., Buhler Choi, Proudfit, & Gebhart, 
2005), drug dependence (e.g., Fredrickson, Boules, Stennett, & Richelson, 2014), anxiety 
(Shilling & Feifel, 2008; Prus, Hillhouse, & LaCrosse, 2014), and schizophrenia (e.g., Holly, 
Ebrecht, & Prus, 2011). Moreover, we previously reported in this journal that the neurotensin 
NTS1 receptor agonist PD149163 improves memory in Brown Norway rats, suggesting that 
activation of NTS1 receptors may improve cognitive functioning in schizophrenia (Keiser et al. 
in press).    
A growing literature exists on the potential involvement of neurotensin in depression and 
the utility of neurotensin receptors agonists for treating depression. Neurotensin NTS1 receptor 
knockout mice have increased immobility time in the tail suspension test as compared to wild-
type controls, which suggests a depression-like phenotype (Fitzpatrick et al., 2012). Direct 
injection of neurotensin into the ventral tegmental area was shown to decrease immobility in a 
forced swim test, an indication of antidepressant-like activity (Cervo, Rossi, Tatarczynska, & 
Samanin, 1992). Brain penetrant NTS1 receptor agonists also exhibit behavioral effects in 
animals models mediated by monoamine neurotransmission. For example, central administration 
of neurotensin (Luttinger et al., 1982) and systemic administration of the NTS1 receptor agonists 
PD149163 (Holly et al., 2011) and NT69L (Hertel, Olsen, & Arnt, 2002) reduces conditioned 
avoidance responding in rats, an effect predictive of clinical antipsychotic efficacy and that is 
mediated by dopamine D2 receptor antagonism (Wadenberg & Hicks, 1999). Moreover, systemic 
administration of the NTS1 receptor agonist NT69L in rats has been shown to increase dopamine 
concentrations in the medial prefrontal cortex, which may be mediated, in part, by serotonin 5-
HT1A receptors (Prus, Huang, Li, Dai, & Meltzer, 2007). 
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A further preclinical evaluation of N-Desalkylquetiapine and a NTS1 receptor agonist 
would aid in evaluating the potential antidepressant effects of these compounds. A reliable 
behavioral procedure for screening antidepressant drugs in animals is the differential-
reinforcement-of-low-rate (DRL) 72 s operant task. In the DRL 72 s procedure, which requires a 
rat to withhold operant responding for 72 s in order to earn a reinforcer, antidepressant drugs 
increase reinforcement rates, decrease response rates, and produce a rightward shift in the 
interresponse time (IRT) distributions (for review, see O’Donnell, Marek, & Seiden, 2005). For 
example, imipramine (Tofranil®; TCA), iproniazid (Marsilid®; MAOI), fluoxetine (Prozac®; 
SSRI), and sertaline (Zoloft®; SSRI) are all antidepressant drugs from different pharmacological 
classes that produce antidepressant-like effects in the DRL 72 s task (Hillhouse & Porter, 2014; 
O’Donnell & Seiden, 1982; O’Donnell & Seiden, 1983; Sokolowski & Seiden, 1999). The DRL 
72 s operant procedure offers high predictive validity and is used as tool for screening novel 
antidepressant drugs. For example, the N-methyl-D-aspartate (NMDA) antagonist ketamine, 
which produces rapid and sustained antidepressant effects in MDD patients, exhibits an 
antidepressant-like profile in the DRL 72 s task (Hillhouse & Porter, 2014).  
Thus, the aim of the present study was to assess antidepressant-like effects of the atypical 
antipsychotic drugs quetiapine, N-Desalkylquetiapine, and the NTS1 receptor agonist PD149163 
using the DRL 72 s task. The atypical antipsychotic drug risperidone, which neither exhibits 
antidepressant effects nor produces an active metabolite with antidepressant effects, the typical 
antipsychotic drug and D2/3 antagonist raclopride, and the tricyclic antidepressant drug 
imipramine, which reliably produces an antidepressant-like profile in the DRL 72 s procedure, 
were assessed for comparison. We hypothesized that quetiapine, N-Desalkylquetiapine, and 
PD149163 would exhibit antidepressant-like effects in this model, whereas risperidone and 
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raclopride would not produce antidepressant-like effects based on previous literature (for review, 
see O'Donnell, Marek, & Seiden, 2005). 
Method 
Subjects 
Twelve adult male Sprague-Dawley rats (Charles River, Portage, MI, USA) weighing 
between 300 and 350 grams at the start of the experiment were housed individually in plastic 
cages in a temperature- and humidity-controlled vivarium kept on a 12-h/12-h light/dark cycle 
(lights on 0700-1900 h). Sprague-Dawley rats were selected because they are commonly used in 
the DRL 72 s procedure (O’Donnell et al., 2005). All testing and training sessions occurred 
during the light cycle, which also was selected based upon other DRL 72 s studies (e.g., 
Hillhouse & Porter, 2014; O’Donnell et al., 2005; O’Donnell & Seiden, 1982). After one week of 
acclimation to the vivarium, daily access to food was restricted in order to maintain the rats at 
85% of their ad libitum weights. Rats had free access to water except during experimental 
sessions. All experimental procedures were approved by the Institutional Animal Care and Use 
Committee at Northern Michigan University and conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals (Institute of Laboratory Animals Resources, 2011). 
Apparatus  
Six identical operant conditioning chambers (29.2 x 30.5 x 24.1 cm) enclosed in sound 
attenuating cubicles were used for the DRL 72 s experiments (Med-Associates, St. Albans, VT, 
USA). Each chamber was equipped with a house light, ventilation fan, two retractable levers, and 
a food pellet dispenser. A house light was mounted on the middle panel of the back wall of each 
chamber. On the opposite wall, a retractable lever (4.5 cm wide, extended 2.0 cm, 3 cm off the 
floor) was mounted on the right side of a food trough. The reinforcers were 45 mg purified diet 
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pellets (Bio-Serv, Frenchtown, NJ, USA). Fans mounted in the sound attenuating cubicles 
provided background white noise. Programming of behavioral sessions and data collection were 
computer controlled by Med-State software (Med PC, Version 4.1, Med-Associates) running on 
a Windows XP operating system. 
Drugs 
The atypical antipsychotic drug quetiapine (NIMH Drug Repository, Bethesda, MD, 
USA), the active quetiapine metabolite, N-Desalkylquetiapine (a gift from NeuroDetective 
International, Wyncote, PA), and the atypical antipsychotic drug risperidone (Sigma-Aldrich, St. 
Louis, MO) were dissolved in sterile water with the aid of 1-2 drops of 85% lactic acid. The 
neurotensin NTS1 receptor agonist PD149163 (gift from the NIHM Drug Repository, Bethesda, 
MD), the tricyclic antidepressant imipramine (Sigma-Aldrich), and the selective D2/3 receptor 
antagonist raclopride L-tartrate (Sigma-Aldrich) were dissolved in 0.9% physiological saline. All 
drugs were administered intraperitoneally (i.p.) in a volume of 1 ml/kg, whereas raclopride was 
administered subcutaneously (s.c.). Drugs, doses, and pretreatment times were as follows: 
quetiapine (2.5-10.0 mg/kg i.p.; 30 min), N-Desalkylquetiapine (2.5-10.0 mg/kg i.p.; 30 min), 
PD149163 (0.0312-0.25 mg/kg i.p.; 30 min), risperidone (0.125-0.5 mg/kg i.p.; 30 min), 
imipramine (2.5-10.0 mg/kg i.p.; 30 min), and raclopride (0.00625-0.05 mg/kg s.c.; 30 min). 
Drug and dose order across rats was counterbalanced using a Latin-square design to minimize 
impact of drug history effects. Doses and administration routes were based on previous literature 
(O’Donnell et al. 2005) and preliminary studies in this laboratory. 
Differential-reinforcement-of-low-rate 72 s procedure 
All rats were first given one session of magazine training in which the house light was 
on, but the levers were not extended into the chamber. During magazine training, one reinforcer 
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(i.e. food pellet) was delivered noncontingently according to a fixed-time 60 s schedule for 30 
min. For the remaining training and test sessions the house light was on and the right lever was 
extended from the wall. During the next three sessions, rats were trained to lever press under a 
fixed-ratio 1 reinforcement schedule, in which each lever press resulted in delivery of a 
reinforcer. Sessions ended after delivery of 30 reinforcers or 60 min, whichever occurred first. 
Following the completion of lever press training, all rats started DRL training. 
Under the DRL schedule, a response produced a reinforcer only after a specified 
interresponse interval had elapsed. Lever presses emitted before expiration of the interresponse 
interval reset the timer and did not produce a reinforcer. The interresponse interval was gradually 
increased over 15 training sessions. Specifically, DRL training began with an 18 s interresponse 
interval for 5 sessions, then was increased to 36 s for 10 sessions, and finally increased to 72 s 
until DRL performance stabilized. DRL performance was considered stable when the number of 
responses for each individual rat did not vary by more than 10% over 5 out of 6 consecutive 
sessions. All DRL training and testing sessions were 60 min in length.  
Once stable performance under the terminal DRL schedule (i.e. 72 s) was established, test 
sessions occurred twice weekly (typically Tuesday and Friday) without training sessions between 
each test session. After the completion of a dose-effect curve for a given drug, the rats received 
at least three training sessions at the start of the dose-effect curve for the next drug. If DRL 
performance remained stable in a given rat after completion of testing with the initial drug, then 
the rat was advanced to testing with another drug. 
Data Analysis 
The three dependent variables were 1) total number of reinforcers delivered during each 
test session, 2) total number of responses during each test session, and 3) inter-response times 
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(IRT) for all responses during each test session. All data were expressed as means (+/- standard 
error of the mean [SEM]). Response and reinforcer data were analyzed using a one-way repeated 
measures analysis of variance (ANOVA), with drug dose as the within subjects factor. IRT 
distributions were obtained by recording responses in nine 12-s bins. To determine if there was a 
shift in the IRT distribution, a two-way repeated measures ANOVA was used with drug dose as 
one within subjects factor and interresponse time as the other within subjects factor. Dunnett’s 
multiple comparisons post hoc tests were conducted, as appropriate. Data were analyzed using 
GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA). 
Results 
Training and baseline performance 
 Eleven of the 12 rats met the training criterion after a mean of 25.27 (± 3.79 SEM) 
training sessions. The remaining rat was removed from the study after failing to meet the training 
criteria within 80 training sessions, which was more than two standard deviations beyond the 
mean number of sessions to criterion for rats that met the training criteria. A repeated measures 
ANOVA using “drug vehicle” as the within subjects factor, with the vehicle data for each drug 
serving as different levels of this factor, did not reveal any significant differences for the number 
of reinforcers earned or the number of responses emitted over the course of the study (data not 
shown). 
Quetiapine 
Figure 1 shows the effects of quetiapine, N-Desalkylquetiapine, and PD149163 on DRL 
72 s performance. Quetiapine produced a significant increase in the number of reinforcers 
obtained, F(3, 27) = 5.61, p = .004, which occurred at a 5.0 and 10.0 mg/kg dose compared to 
vehicle (figure 1a). Quetiapine also significantly altered the number of responses emitted, F(3, 
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27) = 3.19, p = .04, with a 10.0 mg/kg dose of quetiapine leading to a reduction in responses 
compared to vehicle (figure 1b).  
For the IRT distribution, quetiapine produced a significant main effect of IRT time bin, 
F(8, 72) = 9.47, p < .001; no main effect of dose, F(3, 27) = 1.28, p = .30; and a significant 
interaction effect, F(24, 216) = 2.09, p = .003 (Figure 1c). The 5.0 mg/kg dose of quetiapine 
significantly decreased the responses emitted in the 48 s time bin and increased responses 
emitted after 96 s as compared to vehicle, whereas the 10.0 mg/kg dose of quetiapine only 
increased responses emitted after 96 s as compared to vehicle. Overall, these effects indicate that 
a rightward shift in the IRT distribution occurred for these doses, compared to vehicle.  
N-Desalkylquetiapine  
N-Desalkylquetiapine produced a trend toward a statistically significant increase in the 
number of reinforcers earned, F(3, 30) = 2.51, p = .08 (Figure 1d). N-Desalkylquetiapine 
significantly decreased the number of responses emitted, F(3, 30) = 4.27, p = .01 (Figure 1e), 
which occurred at a 5.0 and 10.0 mg/kg dose compared to vehicle.  
For the IRT distribution, N-Desalkylquetiapine produced a significant main effect of IRT, 
F(8, 80) = 15.10, p < .001; no main effect of dose, F(3, 30) = 0.38, p = .77; and a significant 
interaction effect, F(24, 240) = 1.68, p = .03 (Figure 1f). Specifically, the 2.5 mg/kg dose of N-
Desalkylquetiapine decreased responses emitted during the 48 s time bin compared to vehicle. 
The 5.0 mg/kg dose of N-Desalkylquetiapine decreased responses emitted during the 35 s time 
bin, and both 5.0 and 10.0 mg/kg N-Desalkylquetiapine increased responses emitted during the 
72 s time bin compared to vehicle. Overall, these effects indicate that treatment with 5.0 and 10.0 
mg/kg N-Desalkylquetiapine produced a modest rightward shift in the IRT distribution compared 
to vehicle. 
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PD149163 
PD149163 significantly increased the number of reinforcers earned, F(3, 30) = 5.75, p = 
.003 (Figure 1g), and significantly decreased the number of responses emitted, F(3, 30) = 5.50, p 
= .004 (Figure 1h), which occurred at the 0.0625 and 0.125 mg/kg doses as compared to vehicle.  
For the IRT distribution, PD149163 produced a significant main effect of IRT time bin, 
F(8, 80) = 7.19, p < .001; no main effect of dose, F(3, 30) = 0.99, p = .41; and a significant 
interaction of IRT time bin and drug dose, F(24, 240) = 3.52, p < .001 (Figure 1i). Treatment 
with 0.0625 mg/kg PD149163 decreased responses emitted during the 36 s time bin and 
increased responses emitted after 96 s time bins. The high dose of PD149163 (0.125 mg/kg) 
decreased responses emitted in the 24 s, 36 s and 48 s time bins and increased responses emitted 
after 96 s, compared to vehicle. Overall, these effects indicate that treatment with 0.0625 and 
0.125 mg/kg PD149163 produced a rightward shift in the IRT distribution compared to vehicle. 
Risperidone 
Figure 2 shows the effects of risperidone, imipramine, and raclopride on DRL 72 s 
performance. Risperidone produced a significant effect on number of reinforcers earned, F(3, 30) 
= 9.25, p < .001. The 0.25 mg/kg dose increased the number of reinforcers earned, whereas the 
0.5 mg/kg dose did not alter the number of reinforcers earned, compared to vehicle (Figure 2a). 
Risperidone significantly decreased the number of responses emitted during the test session, F(3, 
30) = 7.69, p < .001 (Figure 2b), which occurred at a 0.25 and 0.5 mg/kg dose of risperidone 
compared to vehicle.  
For the IRT distribution, risperidone produced a significant main effect of IRT time bin, 
F(8, 80) = 8.25, p < .001; no main effect of dose, F(3, 30) = 1.85, p = .16; and a significant 
interaction of IRT time bin and drug dose, F(24, 240) = 2.21, p = .001 (Figure 2c). The 0.25 
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mg/kg dose of risperidone decreased responses emitted in the 48 s time bin and increased 
responses emitted in the 84 s and after 96 s time bins compared to vehicle. Additionally, 0.5 
mg/kg risperidone only increased responses emitted after 96 s as compared to vehicle. Overall, 
these results indicate that 0.25 mg/kg risperidone produced a rightward shift in the IRT 
distribution compared to vehicle. 
Imipramine 
Imipramine significantly increased the number of reinforcers earned, F(3, 30) = 8.13, p < 
.001 (Figure 2d), which occurred at the 5.0 and 10.0 mg/kg doses of imipramine compared to 
vehicle. Relative to vehicle, all doses of imipramine (2.5-10.0 mg/kg) significantly decreased the 
number of responses emitted, F(3, 30) = 6.89, p = .001 (Figure 2e).  
For the IRT distribution, imipramine produced a significant main effect of IRT time bin, 
F(8, 80) = 9.08, p < .001; no main effect of dose, F(3, 30) = 1.15 p = .35; and a significant 
interaction of IRT time bin and drug dose, F(24, 240) = 3.96, p < .001 (Figure 2f). Specifically, 
the 2.5 mg/kg imipramine dose decreased the number of responses emitted in the 24 s and 36 s 
time bins and increased responses in the 72 s time bin compared to vehicle. The 5.0 mg/kg dose 
of imipramine failed to significantly alter the IRT distribution compared to vehicle, while the 
high dose of imipramine (10.0 mg/kg) only increased the number of responses after 96 s as 
compared to vehicle. Overall, these result indicate that a 2.5 mg/kg dose of imipramine produced 
a rightward shift in the IRT distribution compared to vehicle. 
Raclopride 
Raclopride significantly decreased the number of reinforcers earned during test sessions, 
F(4, 40) = 6.50, p < .001 (Figure 2g), and significantly decreased the number of responses 
emitted, F(4, 40) = 27.28, p < .001 (Figure 2h). The 0.025 mg/kg dose decreased only responses, 
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whereas the 0.05 mg/kg dose decreased both reinforcers and responses. For the IRT distribution, 
raclopride produced a significant main effect of IRT time bin, F(8, 80) = 8.34, p < .001, significant 
main effect of dose, F(4, 40) = 3.61 p = .01, and a significant interaction of IRT time bin and drug 
dose, F(32, 320) = 6.08, p < .001 (Figure 2i). Specifically, treatment with 0.025 and 0.05 mg/kg 
raclopride decreased responses emitted in the 48 s and 60 s time bins and increased responses 
emitted after 96 s as compared to vehicle.  
Discussion 
The present study found that quetiapine, PD149163, risperidone, and imipramine 
produced antidepressant-like effects using a DRL 72 s task as shown by an increase in 
reinforcers, a decrease in responses, and a rightward shift in the IRT distributions. This is the 
first study to report an antidepressant effect generated by an NTS1 receptor agonist. N-
Desalkylquetiapine produced a partial antidepressant-like effect by decreasing responses and 
producing a rightward shift in the IRT distributions, and provided a trend toward a significant 
increase in the number of reinforcers earned (p = 0.08). Conversely, raclopride decreased both 
the number of reinforcers and responses and flattened the IRT distributions, which is an effect 
consistent with other D2 receptor antagonists tested in the DRL 72 s task (O’Donnell, Marek, & 
Seiden, 2005). 
The antidepressant-like effects produced by quetiapine, PD149163, and risperidone are 
consistent with TCAs (e.g. imipramine and amitriptyline), MAOIs (e.g. tranylcypromine, 
iproniazid, and isocarboxazid), SSRIs (e.g. fluoxetine and sertraline), and atypical antipsychotics 
(e.g. clozapine), which also increase reinforcement rate, decrease response rate and shift the IRT 
distributions to the right (Hillhouse & Porter, 2014; Howard & Pollard, 1984; O’Donnell & 
Seiden, 1982; O’Donnell & Seiden, 1983; Sokolowski & Seiden, 1999). In contrast, the typical 
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antipsychotic drugs haloperidol and raclopride have been shown to decrease both reinforcers and 
responses (Jackson, Koek, & Colpaert, 1995; Seiden, Dahms, & Shaughnessy, 1985; and in the 
present study), indicating a lack of antidepressant effects using the DRL 72 s task.  
The antidepressant-like effects of quetiapine in the present study supports previous 
preclinical and clinical reports suggesting that monotherapy with quetiapine produces 
antidepressant effects. For example, acute administration of quetiapine produces an 
antidepressant-like effect in mice subjected to the forced swim test by decreasing the time spent 
immobile (Kotagale et al., 2013). Additionally, rats treated with chronic administration of 
quetiapine exhibited an anhedonic reduction in sucrose preference that was shown in non-
quetiapine treated rats after acute swim stress and 6 weeks exposure to chronic mild stressors 
(Orsetti et al., 2007; Orsetti et al., 2009). Furthermore, quetiapine XR produces antidepressant 
effects following acute (one week) and chronic (6 to 8 weeks) treatment in adults and elderly 
MDD patients (Bortnick et al., 2011; Cutler et al., 2009; Katila et al., 2013; Weisler et al., 2009).  
N-Desalkylquetiapine produced partial antidepressant-like effects in that N-
Desalkylquetiapine decreased the number of responses and produced a rightward shift in the IRT 
distributions but did not increase the number of reinforcers earned (although there was a trend 
towards significant p = .08). N-Desalkylquetiapine is a potent NET inhibitor and partial 5-HT1A 
agonist and it has a chemical structure similar to the tetracylic antidepressant drug desipramine 
(Jensen et al., 2008). Compounds comparable to this profile, such as the NET inhibitor 
reboxetine and typical antipsychotic drug and tricyclic phenothiazine chlorpromazine, also 
decreased response rates and shifted IRT distributions to the right without significantly 
increasing reinforcement rate in this task (Dekeyne, Gobert, Auclair, Girardon, & Millan, 2002; 
O’Donnell & Seiden, 1983). N-Desalkylquetiapine has also demonstrated an antidepressant 
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effect in a forced swim task in mice (Jensen et al., 2008). Moreover, a reduction in depressive 
symptoms among bipolar disorder patients has been shown to correlate with increased N-
Desalkylquetiapine/quetiapine plasma ratios (Altamura et al., 2012). Taken together, the present 
and earlier findings support the role of an active metabolite contributing to quetiapine’s 
antidepressant effects. 
This was the first study to report an antidepressant-like effect by a neurotensin receptor 
agonist. PD149163 exhibits a high affinity for the neurotensin NTS1 receptor and is devoid of 
activity at monoaminergic, cholinergic, GABAergic, or glutamatergic neurotransmitter receptors 
(Petrie et al. 2004), although PD149163 and other NTS1 receptor agonists exhibit a panoply of 
effects on other neurotransmitter systems. NTS1 receptors are postsynaptically localized in the 
ventral tegmental area, basal ganglia, nucleus accumbens, nucleus basalis magnocellularis, and 
dorsal raphe nuclei (Jolas & Aghajanian, 1997; Binder et al., 2001; St-Galais et al., 2006). 
Intracerebroventricular administration of neurotensin has been shown to increase 5-HT turnover 
in the nucleus accumbens and decrease 5-HT turnover in the ventral tegmental area (Drumheller, 
Gagne, St-Pierre, & Jolicoeur, 1990). Activation of postsynaptic NTS1 receptors in the raphe 
nuclei depolarizes serotonin neurons (Li, Yeh, Tan, Hwang, & Wang, 2001) and facilitates 
serotonin release in the prefrontal cortex (Petkova-Kirova et al., 2008). NTS1 receptors have 
close interactions with dopamine, including presynaptic localization of NTS1 receptors on 
dopamine terminals in the prefrontal cortex and nucleus accumbens. On dopamine terminals, 
activation of NTS1 receptors inhibit dopamine D2 autoreceptor function, leading to a 
disinhibition of dopamine efflux (Binder et al., 2001). Given recent studies describing NTS1 
receptor stimulation as a potential treatment for nicotine (Boules et al., 2011) and the ability of 
these agonist to increase dopamine concentrations in the nucleus accumbens (Sotty et al., 2000; 
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Prus et al., 2007) there is some potential for these compounds to reduce anhedonia in depression 
by elevating dopamine concentrations in the nucleus accumbens (Treadway & Zald, 2011).  
While previous literature has not shown risperidone to exhibit antidepressant effects in a 
DRL 72 s procedure (O’Donnell et al., 2005), risperidone exhibited antidepressant-like effects in 
the present study.  In several clinical case-studies, adjunctive treatment with risperidone has been 
shown to produce rapid (ranging from one day to two weeks) antidepressant effects and reduce 
suicidality (O’Connor & Silver, 1998; Ostroff & Nelson, 1999; Stoll & Haura, 2000). Reeve et 
al. (2008) extended these findings with a double-blind, placebo-controlled study in which 
adjunctive risperidone treatment (0.25-2.0 mg/day) reduced both depressive symptoms and 
suicidality within four days and with effects maintained for the duration of the 8 week study. 
Several preclinical studies have shown that adjunctive risperidone treatment with SSRIs and 
selective serotonin norepinephrine reuptake inhibitors (SNRIs) produces antidepressant-like 
effects by decreasing the time spent immobile in the forced swim test in mice (Dhir & Kulkarni, 
2008) and rats (Iijima, Kurosu, & Chaki, 2010). In the present study, administration of 
risperidone produced antidepressant-like effects in the DRL 72 s task, and in previous studies, 
risperidone has been shown to restore sucrose preference to control levels in rats exposed to 
seven weeks of chronic mild stress (Marston et al., 2011) and to decrease time spent immobile in 
pituitary adenylate cyclase-activating polypeptide (PACAP) knockout mice (Hashimoto et al., 
2009). 
With the exception of PD149163, the compounds tested in the present study all function 
as antagonists for the 5-HT2A receptor (Jensen et al., 2008; Schotte et al., 1996). Like these 
compounds, the serotonin 5-HT2A receptor antagonists ketanserin and ritanserin have produced 
antidepressant-like effects in the DRL 72 s task (Marek, Li, & Seiden, 1989; Marek & Seiden, 
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1988). Further, preclinical research has shown that neuroadaptive changes occur for 5-HT2A 
receptors following behavioral stress procedures and chronic antidepressant treatment. For 
example, an upregulation of 5-HT2A receptors was shown to occur following isolation rearing in 
mice and chronic mild stress exposure in rats, but not in animals given repeated administration 
with citalopram and imipramine, respectively (Günther, Liebscher, Jähkel, & Oehler, 2008; 
Papp, Klimek, & Willner, 1994). Additionally, chronic antidepressant treatment has produced a 
downregulation of 5-HT2A receptors in rat cortex (Papp et al., 1994; Kendall & Nahorski, 1985; 
Lafaille, Welner, & Suranyi-Cadotte, 1991; Paul et al., 1988; Peroutka & Snyder, 1980; Todd, 
McManus, & Baker, 1995). It is possible that antagonism of 5-HT2A receptors produced by the 
compounds in the present study and in previous studies exhibit an effect pharmacologically 
similar to effects engendered by downregulation of 5-HT2A receptors, and which may account for 
the reduced time of onset for antidepressant effects by adjunctive atypical antipsychotic drugs 
found clinically (Bortnick et al., 2011; Cutler et al., 2009; Katila et al., 2013; Ostroff & Nelson, 
1999; Reeve et al., 2008; Weisler et al., 2009).  
Conclusion 
 This study provided an evaluation of the antidepressant effects of two novel and 
pharmacologically different compounds, N-Desalkylquetiapine and PD149163. The behavioral 
findings with N-Desalkylquetiapine add to previous data from preclinical and clinical studies 
suggesting that this compound engenders antidepressant effects. The present study was the first 
to evaluate systemic administration of a NTS1 receptor agonist in an antidepressant screening 
model and revealed that PD149163 engendered, through a very different pharmacological 
mechanism, effects similar to clinically available antidepressant drugs. Further investigation is 
needed to determine if neurotensin NTS1 receptor agonists may produce antidepressant effects in 
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other models, as well as to determine if tolerance may occur to these effects after chronic 
administration. Additional supporting evidence for antidepressant efficacy may establish NTS1 
receptor agonism as a novel pharmacologic strategy for antidepressant drug development.  
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FIGURE CAPTIONS 
Figure 1. Effects of quetiapine (n = 10), N-Desalkylquetiapine (n = 11), and PD149163 (n = 11) 
on DRL 72 s performance in male Sprague-Dawley rats. Left panels (a, d, g) show drug effects 
on number of reinforcers earned (Abscissae: drug dose [mg/kg]; Ordinates: number of 
reinforcers). Center panels (b, e, h) show drug effects on number of responses emitted 
(Abscissae: drug dose [mg/kg]; Ordinates: number of responses). Right panels (c, f, i) show drug 
effects on interresponse time (IRT) distributions (Abscissae: IRT duration [12 s bin]; Ordinates: 
relative frequency of responses). Drug doses are indicated in legends. Filled points represent 
time bin relative frequencies after drug treatment that were significantly different from vehicle as 
determined by two-way ANOVA followed by a Dunnett’s post hoc test. All data were expressed 
as means ± S.E.M. *p < 0.05 and **p < 0.01 for statistically significant differences compared to 
vehicle. 
 
Figure 2. Effects of risperidone (n = 11), imipramine (n = 11), and raclopride (n = 11) on DRL 
72 s performance in male Sprague-Dawley rats. Left panels (a, d, g) show drug effects on 
number of reinforcers earned. Center panels (b, e, h) show drug effects on number of responses 
emitted. Right panels (c, f, i) show drug effects on interresponse time (IRT) distributions. Filled 
points represent time bin relative frequencies after drug treatment that were significantly 
different from vehicle as determined by two-way ANOVA followed by a Dunnett’s post hoc test. 
All data were expressed as means ± S.E.M. *p < 0.05 and **p < 0.01 for statistically significant 
differences compared to vehicle. See figure 1 for other details. 
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